The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study.
Timothy Francis Cloughesy
No relevant relationships to disclose
Paul S. Mischel
No relevant relationships to disclose
Antonio Marcilio Padula Omuro
Consultant or Advisory Role - Novocure; Roche
Michael Prados
No relevant relationships to disclose
Patrick Y. Wen
No relevant relationships to disclose
Bin Wu
Employment or Leadership Position - Sanofi
Kevin Rockich
Employment or Leadership Position - Sanofi
Yi Xu
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Joanne J. Lager
Employment or Leadership Position - Sanofi
Stock Ownership - GlaxoSmithKline; Sanofi
Ingo K. Mellinghoff
No relevant relationships to disclose